Steven Daniels
Interventional Cardiology · San Antonio, TXNPI 1487650008
Payments from drug & device makers
Across 87 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$378
- Merck$190
- Boehringer Ingelheim$157
- Johnson & Johnson$138
- Boston Scientific$128
- Abiomed$111
- plus $789 from 19 others
What the payments were for
- Food & beverage$1,891100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $378 |
| Merck | 6 | $190 |
| Boehringer Ingelheim | 7 | $157 |
| Johnson & Johnson | 8 | $138 |
| Boston Scientific | 8 | $128 |
| Abiomed | 1 | $111 |
| Cardiovascular Systems Inc. | 1 | $102 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $94 |
| Pfizer | 4 | $93 |
| Cvrx, Inc. | 4 | $86 |
| Amarin Pharma, Inc. | 3 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Amgen | 2 | $35 |
| Bayer | 2 | $35 |
| Biotronik Inc. | 1 | $32 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Itamar Medical Inc | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Avinger Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,891 in reported general payments places this provider in the 10th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $23,495 |
| Rosuvastatin Calcium | 42 | $577 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 29 | $549 |
| Losartan Potassium | 43 | $428 |
| Atorvastatin Calcium | 58 | $419 |
| Metoprolol Succinate | 24 | $316 |
| Amlodipine Besylate | 22 | $178 |
| ClopidogrelClopidogrel Bisulfate | 15 | $124 |
| Carvedilol | 19 | $123 |
| Furosemide | 20 | $113 |
| Lisinopril | 13 | $95 |
| Hydrochlorothiazide | 15 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $23,49519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Antonio
- Jorge AlvarezSan Antonio$1.6M
- Robert ChiltonSan Antonio$1.3M
- Marvin EngSan Antonio$756K
- Nandish ThukralSan Antonio$368K
- Anand PrasadSan Antonio$328K
- Jose PerezSan Antonio$312K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.